| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4191059 | Revista de Psiquiatría y Salud Mental | 2016 | 10 Pages |
Abstract
In patients who have not responded to a first-line serotonin-specific reuptake inhibitor therapy, desvenlafaxine-50Â mg was clinically similar in effectiveness, but a less costly option, compared with a weighted average of duloxetine and venlafaxine for the second-line treatment of major depressive disorder patients from a payer (National Health System) perspective in Spain.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Psychiatry and Mental Health
Authors
Javier Rejas Gutiérrez, Milagrosa Blanca Tamayo, Josep Gascón Barrachina, Beatriz Armada Peláez,